Kuldip Gill, MD
Geriatric Medicine · Grass Valley, CANPI 1295882769
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,343 of the $6,720 with a category attached, or 64.6%. 51 manufacturers reported payments, led by Welch Allyn at 35.1% of the total. Reporting peaked in 2021 at $3,404 and has fallen 83.2% since, to $572 in 2025. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Welch Allyn$2K
- GSK$490
- Exact Sciences$284
- Pfizer$262
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$254
- AbbVie$236
- plus $3K from 45 others
What the payments were for
- Food & beverage$4,34365%
- Education$170%
- Other$2,35935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,720 in reported general payments places this provider in the 90th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 412 | $337,071 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 175 | $163,189 |
| JardianceEmpagliflozin | 120 | $113,562 |
| OzempicSemaglutide | 48 | $74,270 |
| JanuviaSitagliptin Phosphate | 99 | $53,936 |
| CreonLipase/Protease/Amylase | 29 | $49,339 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $44,071 |
| XareltoRivaroxaban | 35 | $42,199 |
| MounjaroTirzepatide | 29 | $30,747 |
| MyrbetriqMirabegron | 34 | $28,830 |
| TrulicityDulaglutide | 28 | $27,497 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $26,513 |
| Spiriva RespimatTiotropium Bromide | 31 | $24,432 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $24,237 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $20,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $262 | $337,071412 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix, Arexvy | $490 | $227,487345 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $189 | $153,485167 claims |
| Novo NordiskOzempic | $227 | $74,27048 claims |
| AbbVieCreon, Linzess | $236 | $61,09343 claims |
| MerckJanuvia, Dulera | $23 | $58,820113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $208 | $58,24457 claims |
| Johnson & JohnsonXarelto | $151 | $42,19935 claims |
| AstraZenecaFarxiga, Lokelma | $153 | $24,52949 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $17 | $13,54416 claims |
| NovartisEntresto | $208 | $9,15816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Grass Valley
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
- Douglas ZhangSan Leandro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.